



REP 1001 vs HSV-1




FIG. 1a

REP2001 vs HSV-1




FIG. 1b

REP3007 vs HSV-1




FIG. 1c




FIG. 2

FIG. 3a




FIG. 3b




FIG. 3c




FIG. 3d




FIG. 3e




FIG. 3f





FIG. 3g






FIG. 4

REP 2003 vs HSV-1




FIG. 5a

REP 2009 vs HSV-1




FIG. 5b

REP 2010 vs HSV-1




FIG. 5c

REP 2011 vs HSV-1




FIG. 5d

REP 2012 vs HSV-1




FIG. 5e

REP 2004 vs KOS




FIG. 5f

REP 2006 vs HSV-1




FIG. 5g

REP 2007 vs HSV-1




FIG. 5h

REP 2008 vs KOS




FIG. 5i




FIG. 6

Oligo size vs IC50 (HSV-1)




FIG. 7




FIG. 8a




FIG. 8b




FIG. 8c

REP 2016 vs HSV-1




FIG. 8d

REP 2017 vs HSV-1




FIG. 8e

REP 2018 vs HSV-1




FIG. 8f

REP 2019 vs HSV-1




FIG. 8g

REP2020 vs HSV-1




FIG. 8h

REP 2121 vs HSV-1




FIG. 8i




FIG. 9




FIG. 10




FIG. 11a




FIG. 11b

REP 2059 vs HSV-1




FIG. 11c

REP 2060 vs HSV-1




FIG. 11d




FIG. 12a




FIG. 12b




FIG. 12c




FIG. 13

FIG. 14a




FIG. 14b




FIG. 14c




FIG. 14d




FIG. 14e




FIG. 14f





FIG. 14g



Oligo size versus IC50 (HSV-2)




FIG. 15




FIG. 16a




FIG. 16b




FIG. 16c




FIG. 17a




FIG. 17b




FIG. 17c




FIG. 17d




FIG. 17e




FIG. 17f




FIG. 17g




FIG. 17h




FIG. 17i

Oligo size vs IC50 (CMV)




FIG. 18

REP 2004 vs HIV




FIG. 19a

REP 2006 vs HIV




FIG. 19b

REP 2004 vs MT4 lymphocytes




FIG. 19c

REP 2006 vs MT4 lymphocytes




FIG. 19d

Oligo size vs IC50 (HIV)




FIG. 20

Amprenavir (Agenerase™)




FIG. 21a

Indinavir (Crixivan™)




FIG. 21b

Lopinavir (Kaletra™)




FIG. 21c

Saquinavir (Fortovase™)




FIG. 21d

REP 2003




FIG. 21e

REP 2004




FIG. 21f

REP 2006




FIG. 21g

REP 2007




FIG. 21h

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003

FIG. 22a




FIG. 22b

Amprenavir (Agenerase™)




FIG. 23a

Indinavir (Crixivan™)




FIG. 23b

Lopinavir (Kaletra™)




FIG. 23c

Saquinavir (Fortovase™)




FIG. 23d

REP 2003




FIG. 23e

REP 2004




FIG. 23f

REP 2006




FIG. 23g

REP 2007




FIG. 23h

Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00

FIG. 24




FIG. 25a




FIG. 25b




FIG. 25c




FIG. 25d




FIG. 25e




FIG. 25f




FIG. 25g




FIG. 25h

Oligo size vs IC50 (RSV)




FIG. 26

REP 2006 vs COX B2




FIG. 27a

REP 2006 vs LLC-MK2 cells




FIG. 27b

**FP Serum Interaction test with PS-ODN randomers of increasing size
baseline (unbound bait): 86mP**




FIG. 28a

**REP2006 delivery with DOTAP in 293A cells over time
(50% serum)**




FIG. 28b

Competition test with REP 2006 encapsulated with DOTAP




FIG. 28d

**REP2006 delivery with cytofectin in 293A cells over time
(50% serum)**




FIG. 28c

Competition test with REP 2006 encapsulated with Cytofectin




FIG. 28e




FIG. 29a




FIG. 29b




FIG. 29c




FIG. 30a




FIG. 30b




FIG. 30c

p24 and gp41 binding to HIV lysate




FIG. 31

Bait size vs p24 binding




FIG. 32a

Bait size vs gp41 binding





FIG. 32b

FIG. 33






FIG. 34




FIG. 35a




FIG. 35b




FIG. 35c

REPLICOR compounds versus Vaccinia




FIG. 36

**SEQUENCE COMPOSITION VS ANTI-HSV
EFFICACY**




FIG. 37a

**Effect of sequence composition on efficiency
against HSV-1**




FIG. 37b